{"id":"NCT00160641","sponsor":"UCB Pharma","briefTitle":"A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2005-09-12","resultsPosted":"2013-03-07","lastUpdate":"2020-03-27"},"enrollment":567,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 6.8 Years","timeFrame":"From first dose of CZP to the end of the open-label study (approximately 6.8 years)","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":89.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":67,"countries":["United States","Bulgaria","Croatia","Czechia","Estonia","Israel","Latvia","Lithuania","Poland","Russia","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["32100960","29246162","26353833"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":200,"n":567},"commonTop":["Upper respiratory tract infection","Hypertension","Rheumatoid arthritis","Nasopharyngitis","Activated partial thromboplastin time prolonged"]}}